On Monday, June 30, the lock-in period ended for seven newly listed companies, allowing around 11.2 crore shares worth approximately Rs. 3,623 crore to become eligible for trading, according to CNBC. These shares were previously restricted from being sold. While the end of the lock-in period does not guarantee all shares will be sold immediately, it means they can now be traded on the open market, drawing attention from investors and analysts as well.
Here are three companies with a one-month lock-in expiry on June 30, 2025
Prostarm Info Systems Limited
With a market capitalization of Rs. 863.40 crore, the shares of Prostarm Info Systems Limited were currently trading at Rs. 146.65 per equity share, up nearly 3.31 percent from its previous day’s close price of Rs. 141.95.
On June 30, 2025, the one-month lock-in period for Prostarm Info Systems ends, making 20 lakh shares available for trading. These shares make up 4 percent of the company’s total equity.
Aegis Vopak Terminals Limited
With a market capitalization of Rs. 27,145.79 crore, the shares of Aegis Vopak Terminals Limited were currently trading at Rs. 245 per equity share, down nearly 3.75 percent from its previous day’s close price of Rs. 254.55.
On June 30, 2025, Aegis Vopak Terminals Limited’s one-month lock-in period ends, releasing 2.7 crore shares for trading. These shares represent 2 percent of the company’s total equity.
Schloss Bangalore Limited
With a market capitalization of Rs. 13,418.43 crore, the shares of Schloss Bangalore Limited were currently trading at Rs. 401.60 per equity share, down nearly 2.06 percent from its previous day’s close price of Rs. 410.05.
Schloss Bangalore Limited’s one-month lock-in also expires today, unlocking around 1.8 crore shares. These shares account for 5 percent of the company’s total equity and are now eligible for trading as part of the post-IPO share release.
Here are three companies with a Six-months lock-in expiry on June 30, 2025
Senores Pharmaceuticals Limited
With a market capitalization of Rs. 2,655.22 crore, the shares of Senores Pharmaceuticals Limited were currently trading at Rs. 576.45 per equity share, up nearly 1.51 percent from its previous day’s close price of Rs. 567.90.
On June 30, 2025, the six-month lock-in period for Senores Pharmaceuticals ends, unlocking 2.2 crore shares. These shares represent 48 percent of the company’s total equity and are now eligible for trading.
Sai Life Sciences Limited
With a market capitalization of Rs. 16,055.47 crore, the shares of Sai Life Sciences Limited were currently trading at Rs. 772.50 per equity share, up nearly 1.05 percent from its previous day’s close price of Rs. 764.50.
Sai Life Sciences Limited’s six-month lock-in expires today, making 20 lakh shares available for trade. This accounts for around 0.9 percent of the company’s total equity.
Stanley Lifestyles Limited
With a market capitalization of Rs. 1,974.19 crore, the shares of Stanley Lifestyles Limited were currently trading at Rs. 345.70 per equity share, down nearly 1.21 percent from its previous day’s close price of Rs. 349.95.
Stanley Lifestyles Limited’s six-month lock-in ends today, unlocking 2.1 crore shares. These shares represent approximately 37 percent of the company’s total equity.
Motisons Jewellers Limited
With a market capitalization of Rs. 2,100.84 crore, the shares of Motisons Jewellers Limited were currently trading at Rs. 21.34 per equity share, up nearly 5.75 percent from its previous day’s close price of Rs. 20.18.
Motisons Jewellers Limited’s six-month lock-in period ends today, unlocking 2 crore shares. These shares account for 20 percent of the company’s total equity and are now eligible for trading.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
